培美曲塞联合顺铂或卡铂治疗晚期非小细胞肺癌的临床观察

摘要

Objective To evaluate the efficacy and toxicities of pemetrexed plus cisplatin or carboplatin in the treatment of patients with advanced non-small cell lung cancer( NSCLC). Methods Forty-one patients with ad-vanced NSCLC received pemetrexed plus cisplatin or carboplatin. Results Among the 41 patients advanced NSCLC,the response rate was 26. 8%(11/41),the disease control rate was 63. 4%(26/41);the KPS scores in the 25 patients(61. 0%)were increased. The common toxicities were bone marrow depression and gastrointestinal reaction. Conclusion Pemetrexed plus cisplatin or carboplatin is a safe and effective regimen for the patients with advanced NSCLC.%目的：分析培美曲塞联合顺铂或卡铂治疗晚期非小细胞肺癌（ NSCLC）的疗效及毒副反应。方法41例晚期NSCLC患者接受培美曲塞联合顺铂或卡铂治疗方案。结果41例晚期NSCLC患者中，有效率为26.8%（11/41），疾病控制率为63.4%（26/41）；治疗后有25例患者（61.0%）KPS评分提高；毒副反应主要为骨髓抑制和胃肠道反应。结论培美曲塞联合顺铂或卡铂治疗晚期NSCLC安全有效。